Oxford University Vaccine Trial Stopped Due To Suspected Adverse Reaction
An Individual Is Diagnosed With Transverse Myelitis That Might Be Due To The Drug
The coronavirus vaccine trial that has reached its final phase of testing before its mass manufacturing of the drug has been put on hold after it was observed that multiple individuals in the clinical vaccine trial are suffering from adverse reactions to the medication. The trials are being conducted for the joint collaboration between Oxford University and AstraZeneca in the United Kingdom.
According to the pharmaceutical company Astra Zeneca, the pause between its final stages of vaccine trial is undergoing a routine gap due to an unexpected issue. The finalized outcome of this potential antidote for coronavirus infection is closely being monitored across the world.
The collaboration between AstaZeneca and Oxford University for their coronavirus vaccine trials is seen to be a strong candidate among several coronavirus antidotes that are being developed across the world. According to the schedule made by the firm, this vaccination against the viral infection might become the first one to be introduced in the global market, as the drug has successfully passed through the first two phases of the development of the vaccine trials.
In the past recent weeks, this potential working coronavirus vaccine trial has entered into its third phase, which has more than 30,000 participating individuals that are residing in the United States as well as the United Kingdom, South Africa, and Brazil usually while the development of a vaccine against a pathogen; the third and final phase takes several years to complete before it is approved to be used for mass consumption worldwide.
It has been reported that a volunteer participant of the coronavirus vaccine trial in the United Kingdom has been diagnosed with having transverse myelitis, which is an inflammatory disease of the myelin sheath of the spinal cord, which consequently interrupts the messages sent by the spinal nerves to the central nervous system of the human body. This syndrome is caused by pathogenic infections.
Even though the cause of this disease in the individual is yet to be confirmed and its possible link with the developing coronavirus antidote is being investigated. According to an expert on infectious disease control, it is normal for pauses in any clinical vaccine trials before complete development, and any adverse effects that might be caused by the antidote drugs should be completely checked and regulated.
According to the experts in the United Kingdom, this temporary break, which is taken by AstraZeneca could be a good thing, as it shows that the company prioritizes the wellbeing of the participating volunteers along with the safety of the vaccine being developed. It is possible that people who have taken part in clinical vaccine trials might get ill due to the intake of the drug being tested, as well as natural causes.
The United States President Donald Trump has stated that he wants a potentially working coronavirus vaccine to be available across the United States before the country’s presidential elections that are scheduled to be conducted on November 3. After Trump’s statement, people are concerned that he might prioritize the working politics of the country with the safety of the residents due to the rush order of the vaccine.
On Tuesday, a team of nine pharmaceutical companies that are looking for potentially working coronavirus infection antidote has taken a pledge, saying that they will try to maintain the ethical and scientific standards while exploring for a vaccine.
AstraZeneca is also one of the nine corporations that have taken the pledge to apply for the vaccination’s regulatory approval after the vaccine trials have been completed through its three complete phases. The pledge includes following through all safety regulations as their top priority before it is allowed to spread through for mass consumption.